BST2 and acute myeloid leukemia: Using the Oncolnc database for survival analysis, we also discovered that AML patients with high CD317 expression (CD317High) have shorter overall survival times than those with low CD317 expression (CD317Low) (Fig. 1D), indicating that elevated levels of CD317 contribute to tumor progression, and serve as a key indicator for poor prognosis in HMs.